Four ACON insiders purchased shares in the days leading into tomorrow's earnings — a cluster of buying that stands out against one of the most heavily shorted float profiles in the small-cap health tech space.
The buying started May 6, when a director picked up 1,562 shares at $3.30. CEO Brent Ness followed on May 11, adding 6,289 shares at $3.18 for roughly $20,000. A second director, David K. Neal, bought 2,500 shares the same day. A fourth director bought another 5,664 shares on May 12. Net, insiders added more than 16,000 shares worth just over $50,000 in the past 90 days — small in absolute dollar terms but notable given the stock's micro-cap size and the breadth of participation across the leadership team.
Short sellers are not reading the same signals. SI has more than doubled over the past month, now reaching 33.6% of the free float — a level that makes ACON one of the more aggressively shorted names in its peer group. The ORTEX short score is 72.3, placing the stock in the 4th percentile for short pressure across the universe. Borrow costs have eased from their April highs near 40% APR but remain elevated at roughly 20%. Availability has widened somewhat — the lending pool is not at its tightest — but with the borrow running that expensive, shorts are paying a real carry cost to hold positions into the print. The stock itself has been remarkably flat on the week despite the bearish positioning, adding just 1.5% over the past month to close at $3.28.
The bull-bear divide is sharp. Bulls point to more than $22 million in cash, a growing network of imaging centers and physician users, and a US spine treatment market estimated above $400 million annually. Bears counter that revenue generation remains narrow — almost entirely dependent on Nociscan reports — and that a rising share count has compressed the stock well below prior levels. The sole covering analyst, Ascendiant Capital, maintained a Buy in late March but slashed the target from $23 to $7. That move — a 70% cut in target on a maintained rating — reflects a firm that still believes in the technology but has meaningfully reset its near-term commercial expectations. At $3.28, the stock trades at less than half that revised $7 target, though the gap between price and target should be read in the context of how dramatically the target itself has moved.
Past earnings reactions have been uneven: a 6.7% gain on the day in February reversed into a 22% five-day rally, while a November print saw an immediate 13.9% drop followed by further weakness. That asymmetry — sharp reactions in both directions — frames tomorrow's print as a test of whether the cash runway and early commercial metrics can give the insider buying cluster something to celebrate.
See the live data behind this article on ORTEX.
Open ACON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
